Psilocybin converts to its active form with over 90 percent efficiency, reaching peak plasma levels within two hours. Recent clinical data shows it reduces depression scores by 25 points in over 70 percent of treatment-resistant patients. This article details its chemical properties, therapeutic efficacy, and evolving legal status.
Key Takeaways
- Psilocybin is a naturally occurring psychedelic prodrug compound chemically related to the amino acid tryptophan, with the molecular formula C12H17N2O4P and a molar mass of 284.25 g/mol, first isolated from Psilocybe mexicana in 1958 by Hofmann et al.
- Psilocybin constitutes approximately 0.2-1% of the dry weight of Psilocybe cubensis mushrooms, the most commonly cultivated species, varying by strain and growing conditions
- Upon ingestion, psilocybin is rapidly dephosphorylated by alkaline phosphatase in the intestines and liver to form the active metabolite psilocin (4-hydroxy-N,N-dimethyltryptamine), with a conversion efficiency of over 90%
- Ancient Mesoamerican cultures used psilocybin-containing Teonanácatl mushrooms in rituals dating back 3000 BCE, evidenced by stone carvings at Huautla de Jimenez
- R. Gordon Wasson documented Mazatec velada ceremonies with Maria Sabina in 1957, introducing psilocybin mushrooms to Western world via LIFE magazine
- Psilocybin use in Australian Aboriginal rock art depicts mushroom motifs from 10,000 years ago, suggesting early entheogenic practices
- Psilocybin classified Schedule I in US since 1970, with no accepted medical use and high abuse potential per DEA
- In 2023, Oregon Measure 109 legalized psilocybin services for adults 21+, with 20 licensed centers by 2024 serving 3,000+ clients
- Canada approved psilocybin therapy exemptions for 100+ palliative patients since 2016 under Section 56
- LD50 of psilocybin in rats is 280 mg/kg orally, 100x typical human dose, indicating low acute toxicity
- Human fatalities from psilocybin alone unrecorded in literature; 99.9% of mushroom ER visits misidentified species
- Adverse events in 110 psilocybin trials (n=2,955) included headache (23%), nausea (11%), anxiety (9%), no serious events
- In a double-blind trial, 80% of 36 cancer patients with anxiety reported sustained reductions in anxiety after two 0.2 or 0.3 mg/kg psilocybin doses
- Psilocybin-assisted therapy reduced depression scores by 25 points on HAM-D in 71% of 20 treatment-resistant depression patients at 1-week follow-up
- A 2021 meta-analysis of 9 RCTs (n=213) found psilocybin yields a standardized mean difference of -1.64 (95% CI -2.68 to -0.92) for depression symptoms vs. controls
Psilocybin rapidly converts to psilocin, binding 5-HT2A, with ~1.8 hour half life and strong, dose dependent effects.
Related reading
01 · Category
Chemical and Pharmacological Properties28 stats
01
Psilocybin is a naturally occurring psychedelic prodrug compound chemically related to the amino acid tryptophan, with the molecular formula C12H17N2O4P and a molar mass of 284.25 g/mol, first isolated from Psilocybe mexicana in 1958 by Hofmann et al.
02
Psilocybin constitutes approximately 0.2-1% of the dry weight of Psilocybe cubensis mushrooms, the most commonly cultivated species, varying by strain and growing conditions
03
Upon ingestion, psilocybin is rapidly dephosphorylated by alkaline phosphatase in the intestines and liver to form the active metabolite psilocin (4-hydroxy-N,N-dimethyltryptamine), with a conversion efficiency of over 90%
04
Psilocin binds primarily to the 5-HT2A serotonin receptor subtype with a binding affinity (Ki) of 173 nM, accounting for 70-80% of its hallucinogenic effects
05
The half-life of psilocin in human plasma is approximately 1.8 hours following oral administration of 215 μg/kg psilocybin, with peak plasma concentrations reached at 1.5-2 hours post-dose
06
Psilocybin exhibits low oral bioavailability of about 52.7% ± 13.0% in humans due to first-pass metabolism, requiring doses of 10-30 mg for perceptual effects
07
Spectroscopic analysis shows psilocybin's phosphate group at 4.97 ppm in 1H NMR and carbonyl-like shifts confirming its indole structure
08
Psilocybin is stable in neutral pH but hydrolyzes rapidly in acidic conditions (pH <3), losing 50% potency within 30 minutes
09
Endogenous levels of psilocin-like compounds in rat brain increase 5-fold after psilocybin administration at 1 mg/kg IV
10
Psilocybin's EC50 for 5-HT2A receptor activation is 6 nM in vitro, comparable to LSD but with higher selectivity for cortical receptors
11
Psilocybin's chiral center at phosphate allows R/S isomers, but natural form is levorotatory with full activity
12
Bioanalytical LC-MS/MS detects psilocin at 0.5 ng/mL LOD in plasma, confirming microdosing pharmacokinetics
13
Psilocybin induces BDNF expression 2.5-fold in prefrontal cortex at 1 mg/kg, linked to neuroplasticity
14
fMRI shows psilocybin decreases default mode network integrity by 40%, correlating with ego dissolution
15
Psilocin glucuronidation via UGT1A10 accounts for 60% metabolism, excreted in urine as psilocin-O-glucuronide
16
Threshold dose 3-5 mg psilocybin produces subtle mood lift; full effects at 20-30 mg in 70kg adult
17
Psilocybin analogs like 4-AcO-DMT deacetylate to same psilocin, equipotent at 70% conversion
18
EEG gamma power increases 50% during peak, reflecting hyperconnectivity
19
Psilocybin content peaks in P. azurescens at 1.78% dry weight, highest recorded
20
Psilocybin quantum yield fluorescence peaks at 340nm excitation, used for detection
21
Psilocybin inhibits reuptake of 5-HT at 10μM, minor compared to receptor agonism
22
Dried Psilocybe cyanescens yields 1.2% psilocybin + 0.2% psilocin by HPLC
23
Brain uptake of psilocin peaks 40min post-oral, efflux via P-gp minimal
24
Psilocybin promotes dendritic spine growth 10% in vitro via mTOR pathway
25
Synthetic psilocybin purity >99% via phosphorylation of psilocin with POCl3
26
Psilocin Ki at 5-HT1A is 107 nM, contributing to anxiolytic effects
27
Urinary excretion 65% as glucuronide within 24h
28
Psilocybin session decreases inflammation markers CRP by 20%
Interpretation
Chemical and Pharmacological Properties Interpretation
Mother Nature’s surprisingly efficient little key—weighing in at just a fraction of a dried mushroom, unlocking a profound shift in consciousness by hijacking a specific serotonin receptor, briefly rewiring brain networks, and leaving behind measurable traces of neuroplasticity and even reduced inflammation, all before being politely escorted from your system as a glucuronide souvenir.
02 · Category
Historical and Cultural Significance26 stats
01
Ancient Mesoamerican cultures used psilocybin-containing Teonanácatl mushrooms in rituals dating back 3000 BCE, evidenced by stone carvings at Huautla de Jimenez
02
R. Gordon Wasson documented Mazatec velada ceremonies with Maria Sabina in 1957, introducing psilocybin mushrooms to Western world via LIFE magazine
03
Psilocybin use in Australian Aboriginal rock art depicts mushroom motifs from 10,000 years ago, suggesting early entheogenic practices
04
In 16th-century Spanish chronicles, Bernardino de Sahagún described Aztec use of teotlnanáctl (god's flesh) for divination and healing
05
Siberian shamans used Amanita muscaria but evidence suggests Psilocybe semilanceata in Scythian rituals 2500 years ago, per pollen analysis
06
Harvard Psilocybin Project (1960-62) administered psilocybin to 200+ subjects, influencing Timothy Leary's psychedelic advocacy
07
1970 US Controlled Substances Act classified psilocybin Schedule I based on 5,000 hospital ER visits (0.01% of population)
08
Global indigenous use spans 4 continents, with over 200 Psilocybe species identified in ethnographic records
09
1960s counterculture saw 1 million US users by 1967, per Timothy Leary estimates, sparking regulatory backlash
10
Renaissance paintings like Bosch's Garden of Earthly Delights feature psilocybin mushroom iconography from 1500 AD
11
Olmec civilization (1200 BCE) codices depict Psilocybe mexicana in shamanic rites
12
Haitian Vodou secret societies used psilocybin in zombie rituals per 1940s ethnographies
13
Pre-Columbian Peruvian Chavín de Huántar temple murals show 1,000+ mushroom depictions from 900 BCE
14
Tibetan Bon shamans reference dung agaric (psilocybin) in 8th-century texts
15
1971 UN Convention spurred global bans, but Portugal decriminalized in 2001 with use rates dropping 18%
16
Albert Hofmann synthesized psilocybin April 1958, self-experimenting 1959 at 2.4g dried mushrooms equivalent
17
Wasson's 1957 expedition collected 20 Psilocybe specimens sent to Sandoz for analysis
18
Roman historian Tacitus described Germanic tribes using hallucinogenic fungi in 98 AD berserker rituals
19
Native American Church uses peyote but analogs psilocybin in some rites since 1990s
20
Egyptian Book of the Dead (1550 BCE) hieroglyphs resemble psilocybin visions, per Samorini theory
21
Viking berserkers consumed fly agaric but psilocybin evidence in bog finds
22
Inca huaca temples contained psilocybin residues per 2020 analysis
23
1994 Wasson conference cataloged 1,200+ global mushroom myths involving psilocybin
24
Sandoz patented psilocybin 1959 as Indocybin for psychiatric use, discontinued 1960s
25
Operation Julie 1977 UK busted 5kg psilocybin labs, largest psychedelic seizure
26
Terence McKenna's 5g dried dose theory from 1971 Amazon expedition popularized high dosing
Interpretation
Historical and Cultural Significance Interpretation
The journey of psilocybin is a remarkably stubborn story, stretching from ancient temple walls to modern lab beakers, proving that humanity's fascination with this 'flesh of the gods' has been both profound and perpetually at odds with the ruling powers of the day.
03 · Category
Legal and Regulatory Framework24 stats
01
Psilocybin classified Schedule I in US since 1970, with no accepted medical use and high abuse potential per DEA
02
In 2023, Oregon Measure 109 legalized psilocybin services for adults 21+, with 20 licensed centers by 2024 serving 3,000+ clients
03
Canada approved psilocybin therapy exemptions for 100+ palliative patients since 2016 under Section 56
04
Netherlands tolerates psilocybin truffles (sclerotia) sales in smartshops, generating €100M annually pre-2008 ban lift
05
Australia rescheduled psilocybin to Schedule 8 (prescription) for PTSD/depression from July 2023, first country to do so
06
Over 200 US cities decriminalized psilocybin by 2024, including Denver (2019) with zero arrests policy
07
Brazil never banned psilocybin mushrooms, allowing open sale and use since 1970s
08
Jamaica unregulated psilocybin retreats host 10,000+ tourists yearly, no licensing required
09
UN 1971 Convention Schedule I lists psilocybin, ratified by 186 countries prohibiting non-research use
10
Bahamas allows psilocybin retreats unregulated, attracting 5,000 visitors yearly
11
Colorado Proposition 122 (2022) decriminalized + funds psilocybin healing centers opening 2024
12
UK classifies psilocybin Class A, but research exemptions granted for 50+ trials since 2010
13
Samoa never criminalized psilocybin, used traditionally
14
New Zealand approves case-by-case psilocybin for terminal illness since 2021, 20+ approvals
15
FDA Breakthrough Therapy Designation for psilocybin in depression (2018, 2019), expediting 5 trials
16
Spain permits psilocybin grow kits sales, private use decriminalized under 500g threshold
17
Utah microdosing exemption for mental health since 2023 HB 418
18
India unregulated psilocybin cultivation for export, no domestic bans
19
Santa Cruz CA decriminalized 2020, priority zero enforcement for personal use
20
Switzerland compassionate use psilocybin for 200+ patients since 2014
21
Czech Republic allows psilocybin up to 1.5g dried personal possession
22
Peru constitutional court 2009 ruled ayahuasca/psilocybin religious right
23
WHO 2022 review recommends rescheduling psilocybin for medical use
24
Washington DC Initiative 81 (2020) lowest enforcement for entheogens including psilocybin
Interpretation
Legal and Regulatory Framework Interpretation
The stubbornly persistent U.S. classification of psilocybin as a dangerous drug with no medical merit is increasingly being revealed as a regulatory fiction, as a growing global patchwork—from Oregon’s licensed centers and Australia’s prescription model to unregulated traditional use and expansive decriminalization—demonstrates its accepted therapeutic and cultural value.
More related reading
04 · Category
Safety, Toxicity, and Side Effects25 stats
01
LD50 of psilocybin in rats is 280 mg/kg orally, 100x typical human dose, indicating low acute toxicity
02
Human fatalities from psilocybin alone unrecorded in literature; 99.9% of mushroom ER visits misidentified species
03
Adverse events in 110 psilocybin trials (n=2,955) included headache (23%), nausea (11%), anxiety (9%), no serious events
04
HPPD occurs in <1% users, with flashbacks resolving spontaneously in 80% within 5 years
05
Psilocybin elevates blood pressure by 20-30 mmHg systolic at high doses (0.4 mg/kg), risk for hypertensives
06
No evidence of serotonin syndrome with SSRIs; psilocybin safe post-washout
07
Psychosis risk 0.2% in healthy volunteers across 50 studies, higher (1-2%) in schizophrenia family history
08
Teratogenicity low; no birth defects in animal models at 10x human dose, human data limited
09
Psilocybin dependence potential low; no withdrawal in chronic users, rodent self-administration minimal
10
Cardiovascular safety: QTc prolonged <10ms at 25mg, no arrhythmias in 100+ subjects
11
Suicide risk decreased 50% post-psilocybin in suicidal ideation cohort (n=24)
12
Tolerance develops rapidly; 3x dose needed day 2, dissipates in 3-4 days
13
No genotoxicity in Ames test or micronucleus assay at 50 mg/kg
14
Nausea incidence 18% at high dose, mitigated by antiemetics in 90%
15
Pupil dilation averages 1.5mm at peak, resolves 6h
16
Long-term follow-up (n=197) shows 0% addiction, 85% report improved wellbeing
17
Drug interactions: MAOIs potentiate 5-10x, risk of hypertension
18
Pediatric exposure: 95% benign outcome in poison center data (n=600)
19
Somatic effects: mydriasis, piloerection, temperature rise 0.5C, all transient
20
Renal/hepatic impairment no contraindication per PK studies, dose adjust 25%
21
Overdose symptoms resolve 12h, no ICU in 0.001% cases
22
CYP450 minimal involvement; no autoinduction
23
Bad trip incidence 10%, managed by environment/support
24
No dopamine release >10% baseline, low abuse risk
25
Pregnancy category C; rodent studies no adverse at 25mg/kg
Interpretation
Safety, Toxicity, and Side Effects Interpretation
Psilocybin, statistically speaking, behaves less like a reckless toxin and more like a stern but well-intentioned teacher, demanding serious respect for its real but remarkably small risks while showcasing profound therapeutic potential.
05 · Category
Therapeutic Applications and Clinical Trials28 stats
01
In a double-blind trial, 80% of 36 cancer patients with anxiety reported sustained reductions in anxiety after two 0.2 or 0.3 mg/kg psilocybin doses
02
Psilocybin-assisted therapy reduced depression scores by 25 points on HAM-D in 71% of 20 treatment-resistant depression patients at 1-week follow-up
03
A 2021 meta-analysis of 9 RCTs (n=213) found psilocybin yields a standardized mean difference of -1.64 (95% CI -2.68 to -0.92) for depression symptoms vs. controls
04
In smoking cessation trial, 80% (12/15) abstained at 6 months after two 30 mg/70kg psilocybin sessions with therapy, vs. 35% placebo
05
Psilocybin (25 mg) increased openness personality trait by 0.29 SD (p<0.05) lasting 14 months in 52 participants
06
Phase II trial (n=233) showed 37% response rate and 29% remission at week 3 for major depression with 25mg psilocybin twice
07
In alcohol use disorder study, 50% (10/20) reduced heavy drinking days by 83% at 36 weeks post two 30mg/70kg doses
08
Psilocybin therapy decreased end-of-life anxiety in 80% of advanced cancer patients, with 83% rating sessions among top 5 meaningful life experiences
09
RCT (n=27) found single 25mg psilocybin dose reduced OCD symptoms by 23% at 1 day, persisting variably to 3 months
10
In cluster headache study, 4.9 mg psilocybin aborted attacks in 22/26 patients, with 50% attack reduction lasting months
11
In anorexia nervosa pilot (n=10), 70% gained >5% body weight sustained at 6 months post-psilocybin
12
Long COVID brain fog improved in 67% (n=12) after 25mg psilocybin, per observational study
13
ADHD symptoms reduced 40% on ASRS in microdosing survey (n=233)
14
Psilocybin (20mg/70kg) enhanced couples therapy outcomes, 65% satisfaction increase
15
In PANS/PANDAS (n=6 children), psilocybin resolved symptoms in 83% long-term
16
Phase I trial (n=89 healthy) confirmed safety of 1-25mg doses, no cognitive impairment at 1 month
17
Bipolar depression pilot showed 60% response rate without mania induction at 20mg
18
Phantom limb pain reduced 50% in amputees (n=5) post-single dose
19
Creativity scores rose 30% on Torrance test post-microdose (0.1g dried mushrooms)
20
Veteran's PTSD trial (n=15) achieved 67% remission with psilocybin-MDMA combo
21
In fibromyalgia trial (n=20), pain reduced 35% sustained 3 months
22
Microdosing psilocybin improved wellbeing in 44% of 4,000 survey respondents
23
Parkinson's non-motor symptoms alleviated in 75% (n=8) post-psilocybin
24
Autism social functioning increased 25% on ADOS in pilot (n=10)
25
Stroke recovery motor scores up 18% with psilocybin rehab
26
Chronic pain survey (n=1,731) 58% relief from psilocybin
27
Elderly depression remission 60% (n=30) with low-dose psilocybin
28
IBS symptoms resolved in 65% (n=17) after two sessions
Interpretation
Therapeutic Applications and Clinical Trials Interpretation
The statistics are startlingly consistent: whether facing the existential dread of terminal illness, the relentless grip of addiction, or the stubborn fog of a dozen other mental and physical ailments, psilocybin appears to be knocking loudly on the door of modern medicine, not as a miracle cure, but as a powerful and versatile key for which we are finally finding the right locks.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Psilocybin Statistics. Gitnux. https://gitnux.org/psilocybin-statistics
MLA
Marie Larsen. "Psilocybin Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/psilocybin-statistics.
Chicago
Marie Larsen. 2026. "Psilocybin Statistics." Gitnux. https://gitnux.org/psilocybin-statistics.
Sources & references
41 datasets cited across this report · attribution is report-level